《異動股》國際商業數字技術(01782.HK)逆市續漲28%屢創上市新高
恆指在金融、新經濟、內房及內需股沽壓疲弱主導,午後跌幅曾擴至513點或2.7%低見18,562喘定,現報18,653,急吐422點或2.2%,總成交額753億元。
然而,國際商業數字技術(01782.HK)連續第二天逆市創2016年12月上市以來新高,最高見7.42元,現報7.4元,逆市續升28%,一向薄弱成交急至439萬股,涉資3,124萬元。
原名「飛思達科技」於本月12日起正式易名為「國際商業數字技術」,以反映該公司於5月中旬宣布擬進一步發展其軟件開發服務及技術服務到中央銀行數字貨幣(CBDC)網絡系統之新業務市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.